First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer

The efficacy and safety of continuing multiple anti-HER2 therapies in advanced breast cancer (ABC) patients remains unclear. This study investigated eribulin in combination with pertuzumab and trastuzumab for both taxane- and trastuzumab-pretreated HER2-positive ABC patients. In a single-institute,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast (Edinburgh) 2017-10, Vol.35, p.78-84
Hauptverfasser:	Araki, Kazuhiro, Fukada, Ippei, Yanagi, Hiroyo, Kobayashi, Kokoro, Shibayama, Tomoko, Horii, Rie, Takahashi, Shunji, Akiyama, Futoshi, Ohno, Shinji, Ito, Yoshinori
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Agents, Immunological - administration & dosage Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Disease-Free Survival Dose-Response Relationship, Drug Eribulin Female Furans - administration & dosage HER2-positive advanced breast cancer Humans Ketones - administration & dosage Middle Aged Non-taxane microtubule dynamic inhibitor Pertuzumab Receptor, ErbB-2 - metabolism Trastuzumab Trastuzumab - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!